Prognostic Role of Serum Alpha-Fetoprotein in Hepatocellular Carcinoma Patients with Radiofrequency Ablation (original) (raw)

Abstract

Background and study aim: Prognostic value of serum alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC) is still debatable. We aimed to study this role in HCC patients who underwent radiofrequency ablation (RFA). Materials and Methods: Records from HCC patients were retrospectively analyzed between January 2012 and December 2016. A minimum data set for each patient record of a follow-up period of at least 1 year was pre-defined before enrollment. In all, 153 patients were enrolled. AFP levels were recorded for all patients at the time of diagnosis, 1 month after RFA and at 3-month intervals afterward. Patients were divided according to pretreatment AFP level into 3 groups: group 1: AFP <20 ng/mL, group 2: AFP 20-200 ng/mL and group 3: AFP >200 ng/mL. Results: Pretreatment AFP is not significantly correlated with age, baseline lesion number or size, baseline Child score or class, post RFA recurrence or death. The overall survival rates were 95%, 75.6%, 55.6%, 48.8%, and 48.8% at 1,2,3,4, and 5 years respectively. On comparing the 3 groups on disease-free survival, there was no statistically significant difference among the three classes. Child class A patients showed statistically significant better survival after RFA than those with Child class B. The ROC curve showed that AFP had inadequate accuracy to discriminate survivors and deceased patients and to discriminate patients with recurrence from those without recurrence. Conclusion: AFP level could not be used as a good predictor of either death or recurrence of HCC after RFA

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (25)

  1. Khalifa et al., Afro-Egypt J Infect Endem Dis 2018; 8(4): 164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx Khalifa et al., Afro-Egypt J Infect Endem Dis 2018(4):164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx Khalifa et al., Afro-Egypt J Infect Endem Dis 2018; 8(4): 164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx Khalifa et al., Afro-Egypt J Infect Endem Dis 2018(4):164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx Khalifa et al., Afro-Egypt J Infect Endem Dis 2018; 8(4): 164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx Khalifa et al., Afro-Egypt J Infect Endem Dis 2018(4):164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx REFERENCES
  2. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.
  3. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.
  4. Bruix J, Sherman M;,American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
  5. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-10.
  6. Huo TI, Lee SD. Role of the model for end-stage liver disease and serum a-fetoprotein as predictors for hepatocellular carcinoma. Liver Int 2006; 26: 1300-1.
  7. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
  8. Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J Hepatol 2012; 56: 1112-1120
  9. Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of early alpha- fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279
  10. Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, et al. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg 2013; 37: 820-828.
  11. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107:569-577.
  12. N'Kontchou G, Mahamoudi A, Aout M, Ganne- Carrié N, Grando V, Coderc E, et al. Radio- frequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-1483.
  13. Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, et al. Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis. Radiology 2014; 270: 900-9.
  14. Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RS, Diniz MA, et al. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World J Gastroenterol 2014; 20: 1585-1593.
  15. Shinozuka K, Shibata T, Imamine R, Kataoka M and Togashi K. Effectiveness of Radiofrequency Ablation of Initial Recurrent Hepatocellular Carcinoma after Hepatectomy: Long-Term Results and Prognostic Factors. Open Journal of Radiology 2017; 7: 177-189.
  16. Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha- Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma Identified During Surveillance in Compensated Cirrhosis. Hepatology 2012; 56: 1371-9.
  17. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001; 92: 126-135.
  18. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700- 1707.
  19. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129- 137.
  20. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting Khalifa et al., Afro-Egypt J Infect Endem Dis 2018; 8(4): 164-371 https://aeji.journals.ekb.eg/ http://mis.zu.edu.eg/ajied/home.aspx list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
  21. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepato- cellular Carcinoma: Both or Neither? Am J Gastroenterol 2006; 101: 524-532.
  22. Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S, Tani M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg 2011; 254: 984-991.
  23. Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is Serum Alpha-Fetoprotein Useful for Predicting Recurrence and Mortality Specific to Hepatocellular Carcinoma After Hepatectomy? A Test Based on Propensity Scores and Competing Risks Analysis. Ann Surg Oncol 2012; 19: 3687- 3696.
  24. Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, et al. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepato- cellular carcinoma. Liver International 2014; 34: 313-321.
  25. Zhang W, Luo E, Gan J, Song X, Bao Z, Zhang H, et al. Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound. World J Surg Oncol 2017; 15: 122-128.